Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Osteonecrosis

sorafenib has been researched along with Osteonecrosis in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P1
Canzano, F; Di Lella, F; Manuguerra, R; Vincenti, V1
Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F1
Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P1

Reviews

1 review(s) available for sorafenib and Osteonecrosis

ArticleYear
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Current medicinal chemistry, 2017, Volume: 24, Issue:28

    Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib

2017

Other Studies

4 other study(ies) available for sorafenib and Osteonecrosis

ArticleYear
Osteonecrosis of the External Auditory Canal Associated With Oral Sorafenib Therapy: Sorafenib and Temporal Bone Osteonecrosis.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2019, Volume: 40, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Ear Canal; Ear Diseases; Humans; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Sorafenib; Temporal Bone

2019
Sorafenib: osteonecrosis of the jaw.
    Prescrire international, 2015, Volume: 24, Issue:165

    Topics: Antineoplastic Agents; Humans; Jaw; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib

2015
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
    Tumori, 2016, Nov-11, Volume: 102, Issue:Suppl. 2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Jaw; Liver Neoplasms; Male; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed

2016
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012